Under construction – not a live service
Sign in

NCT05866679SuspendedPhase 1

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Source: ClinicalTrials.gov · Last updated 6 Oct 2026

Reason given: Suspension

Brief summary (registry, in English)

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.

Status (registry)
Suspended
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
30 (estimated)
First submitted
10 May 2023
Start date
12 Apr 2024
Primary completion date
31 Aug 2028
Lead sponsor
M.D. Anderson Cancer Center
NCT number
NCT05866679

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • (all cohorts)
  • Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.

Who the study is looking for

  • For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson:
  • Patients with a first degree relative (mother, sister, or daughter) with ovarian cancer or
  • A personal history of breast cancer before age 40 or
  • A personal history of breast cancer diagnosed before age 50, and one or more close relatives diagnosed with breast or ovarian cancer at any age. Two or more close relatives diagnosed with breast cancer before age 50 or with ovarian cancer diagnosed at any age or
  • Ashkenazi Jewish heritage and a personal history of breast cancer before age 50 or
  • Ashkenazi Jewish heritage and a first- or second-degree relative diagnosed with breast cancer before age 50 or with ovarian cancer at any age or
  • Presence of a BRCA1 or BRCA2 mutation or
  • Presence of a mismatch repair gene mutation associated with a hereditary cancer syndrome known as Hereditary Non-Polyposis Colon Cancer (HNPCC)/Lynch syndrome. For the second cohort- 10 Patients will be enrolled who present to MD Anderson for a pelvic ultrasound or have an outside ultrasound or imaging study without a mass or have an adnexal mass (benign) on outside imaging and do not have a high risk for ovarian cancer.
    • For the third cohort of patients:
    • 10 patients who have suspicion of ovarian malignancy on conventional imaging and will be undergoing surgical resection will be included.

Age in the registry: 18 months to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
M D Anderson Cancer CenterHoustonUnited StatesUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.